Long-term studies are needed to evaluate the sustained efficacy and safety of SGLT2 inhibitors and GLP-1 RAs, particularly in diverse and underrepresented subpopulations, such as patients with advanced chronic kidney disease or those at high cardiovascular risk with limited comorbidities. Here, GLP1R is linked to chronic kidney disease.